Autoantibodies, specifically IgG1 and IgG3 subclasses against β2-adrenergic and M2-muscarinic receptors, appear in up to 70% of CRPS patients [123,124,125,126,127,128,129,130,131]. This evidence concerns the gene CHRM2 and complex regional pain syndrome.